MediPines Corporation announced it has received FDA 510(k) market clearance on its new non-invasive medical device, the
The MediPines Gas Exchange Monitor is the first technology of its kind to integrate a comprehensive set of respiratory parameters and innovative indices analyzed from a patient’s normal breathing samples in a simple, easy to administer breathing test in only a few minutes.
This non-invasive monitor empowers clinicians by providing point of care information on pulmonary gas exchange previously only available through invasive or complicated methods. The MediPines Gas Exchange Monitor provides critical parameters including respiratory rate, oxygen saturation, pulse rate, respiratory quotient and end-tidal CO2. It is the only device that provides novel indices such as oxygen deficit, conveniently packaged in a single, portable, light weight device.
“This is a result of years of scientific and medical research working with the world-renowned respiratory physiology team led by Dr. John B. West,” says Steve Lee, CEO of MediPines Corporation. In the US, over 33 million patients suffer from respiratory diseases. Globally, over 350 million patients suffer from chronic to acute respiratory issues ranging from Chronic Obstructive Pulmonary Disease (COPD) to asthma. For published studies and findings.
According to CEO, “This device is a significant step forward in advancing respiratory medicine, providing hospitals with vital respiratory care measurements to aid clinicians in diagnosis and treatment, immediately at the point-of-care.”
MediPines Corporation is a pioneering medical device company established to advance respiratory medicine. The company is based in Orange County, California and is focused on innovative devices for respiratory diagnostics and management by partnering with world-class medical institutions, focusing on patient outcomes, and achieving meaningful long-term results.